Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

Vorinostat and Lenalidomide After Autologous Stem Cell Transplant in Treating Patients With Multiple Myeloma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00729118
Recruitment Status : Completed
First Posted : August 7, 2008
Last Update Posted : May 18, 2020
Merck Sharp & Dohme LLC
Information provided by (Responsible Party):
Yvonne Efebera, Ohio State University Comprehensive Cancer Center

Brief Summary:

RATIONALE: Vorinostat may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Lenalidomide may stop the growth of multiple myeloma by blocking blood flow to the cancer. Giving vorinostat together with lenalidomide may kill more cancer cells.

PURPOSE: This phase I trial is studying the side effects and best dose of vorinostat when given together with lenalidomide after autologous stem cell transplant in treating patients with multiple myeloma.

Condition or disease Intervention/treatment Phase
Multiple Myeloma Plasma Cell Neoplasm Drug: lenalidomide Drug: vorinostat Phase 1

Detailed Description:



  • To assess the dose-limiting toxicities and safety of vorinostat and lenalidomide after autologous peripheral blood stem cell transplantation in patients with multiple myeloma.
  • To evaluate the overall response rate to the combination of Vorinostat (SAHA) and lenalidomide.


  • To evaluate the effect of this treatment regimen on natural killer cell activity and regulatory T cells in the post-transplant period.
  • To determine preliminary clinical activity of this treatment regimen by assessing overall survival and progression-free survival of these patients.
  • To obtain pilot data regarding an association between this treatment regimen and patient quality of life and circulating inflammatory cytokines.

OUTLINE: This is a dose-escalation study of vorinostat.

Patients receive oral vorinostat alone once daily on days 1-21 in course 1. For the second and subsequent courses, patients receive oral vorinostat in combination with oral lenalidomide once daily on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.

Patients undergo blood sample collection periodically for correlative laboratory studies. Studies include functional immune assays (T-cell and natural killer cell activity and regulatory T-cell recovery) by fluorescence activated cell sorting (FACS) or ELISPOT; analysis of inflammatory markers (cytokines and catecholamines); and analysis of global H3 and H4 acetylation by immunohistochemistry.

Quality of life is assessed periodically using the Brief Pain Inventory (Short Form), The Center for Epidemiologic Studies Depression Scale (CES-D-10), a 9-item Brief Fatigue Inventory, and the FACT-G questionnaires.

After completion of study treatment, patients are followed for at least 30 days.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 19 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Vorinostat (SAHA) and Lenalidomide After Autologous Transplant for Patients With Multiple Myeloma
Actual Study Start Date : September 26, 2008
Actual Primary Completion Date : December 26, 2019
Actual Study Completion Date : May 4, 2020

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Multiple Myeloma

Arm Intervention/treatment
Experimental: Lenalidomide + Vorinostat
Maintenance post autologous transplant
Drug: lenalidomide
combined with Vorinostat (SAHA) days 1-21 of a 28-day cycle until progression or clinically significant toxicity.
Other Names:
  • Revlimid
  • CC-5013

Drug: vorinostat
Vorinostat (SAHA) will be administered orally beginning at dose level 1 starting day +90 ±6 days after HSCT for days 1 and 15-21 of a 28-day cycle combined with lenalidomide days 1-21 of a 28-day cycle until progression or clinically significant toxicity.
Other Names:
  • SAHA
  • Suberoylanilide hydroxamic acid

Primary Outcome Measures :
  1. Safety of patients receiving SAHA and lenalidomide following autologous PBSCT [ Time Frame: up to 3 years ]
    Patients will be assessed for Adverse events using the NCI CTCAE version 4.0 criteria

Secondary Outcome Measures :
  1. Duration of response [ Time Frame: up to 3 years ]
    The time from progression to death

  2. Time to progression (TTP) [ Time Frame: up to 3 years ]
    Patients will be assessed for TTP from the start of treatment until the date of progression.

  3. Progression-free survival (PFS) [ Time Frame: up to 3 years ]
    PFS is the time from the first dose a patient receives until disease progression or death at trial closure.

  4. Time to response [ Time Frame: up to 3 years ]
    From the first dose of study therapy until measurement criteria are first met progressive response (PR), complete response (CR) or stable disease (SD). The patients best response is recorded.

  5. Duration of overall response [ Time Frame: up to 3 years ]
    The duration computed for subjects whose best response is either PR or CR or SD and is measured when first met for complete or partial response(whichever comes first) until first date of progressive disease or death

  6. Overall survival [ Time Frame: up to 3 years ]
    The survival time defined as the time from start of treatment to the date of death.

  7. Response rate [ Time Frame: up to 3 years ]
    Tumor response defined as the total number of patients whose best response is PR or CR or SD, divided by the number of patients

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No


  • Diagnosis of multiple myeloma
  • Has undergone melphalan-conditioned autologous peripheral blood stem cell transplant myeloma.


  • ECOG/WHO performance status 0-2
  • ANC ≥ 1,000/mm³
  • Platelet count ≥ 75,000/mm³
  • Total bilirubin ≤ 2 times upper limit of normal (ULN)
  • AST and ALT ≤ 2 times ULN
  • Serum creatinine ≤ 1.5 times ULN OR creatinine clearance ≥ 50 mL/min
  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use effective contraception during and for 90 days after completion of study treatment
  • No blood, sperm, or ova donation during and for ≥ 4 weeks after completion of study treatment
  • Able to obtain commercially available lenalidomide via Celegene's RevAssist® program

    • Registered in the RevAssist® program
    • Willing and able to comply with the requirements of RevAssist®
  • Able to swallow capsules
  • No severe or uncontrolled systemic illness
  • No "currently active" second malignancy, other than nonmelanoma skin cancer or carcinoma in situ of the cervix

    • Patients are not considered to have a "currently active" malignancy if they completed therapy for the malignancy, are disease free from the malignancy for > 5 years, and are considered by their physician to be at < 30% risk of relapse
  • No congenital long QT syndrome
  • No drug or alcohol abuse within the past 12 months
  • No history of allergic reactions (including erythema nodosum) attributed to compounds of similar chemical or biologic composition to lenalidomide, thalidomide, or vorinostat
  • No other medical condition, including mental illness or substance abuse, deemed by the investigator(s) to likely interfere with a patient's ability to sign informed consent, cooperate and participate in the study, or interfere with the interpretation of the study results


  • See Disease Characteristics
  • More than 4 weeks since prior class Ia, Ib, or Ic antiarrhythmic medication
  • No prior HDAC inhibitor-like compounds (e.g., valproic acid) as anticancer therapy
  • More than 30 days since prior HDAC inhibitor-like compounds for other indications (e.g., valproic acid for epilepsy)
  • No prior gastrointestinal surgery or other procedure that may, in the opinion of the investigator, interfere with the absorption or swallowing of the study drugs
  • No concurrent corticosteroids other than for physiologic maintenance treatment
  • No concurrent radiotherapy, unless for local control of bone pain

    • Irradiated area should be as small as possible
    • Lesions within the irradiated field cannot be used for response assessment
  • No concurrent use of complementary or alternative medicines that would confound the interpretation of toxicities and anticancer activity of the study drugs
  • No other concurrent anticancer therapy, including chemotherapy or biologic therapy
  • No other concurrent HDAC inhibitors (e.g., valproic acid)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00729118

Layout table for location information
United States, Ohio
Ohio State University
Columbus, Ohio, United States, 43210
Sponsors and Collaborators
Ohio State University Comprehensive Cancer Center
Merck Sharp & Dohme LLC
Layout table for investigator information
Principal Investigator: Yvonne C. Efebera, MD Ohio State University Comprehensive Cancer Center
Additional Information:
Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Yvonne Efebera, Principal Investigator, Ohio State University Comprehensive Cancer Center Identifier: NCT00729118    
Other Study ID Numbers: OSU-08001
NCI-2011-03140 ( Registry Identifier: Clinical Trial Reporting Program (CTRP) )
First Posted: August 7, 2008    Key Record Dates
Last Update Posted: May 18, 2020
Last Verified: May 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Yvonne Efebera, Ohio State University Comprehensive Cancer Center:
stage I multiple myeloma
stage II multiple myeloma
stage III multiple myeloma
refractory multiple myeloma
Additional relevant MeSH terms:
Layout table for MeSH terms
Multiple Myeloma
Neoplasms, Plasma Cell
Neoplasms by Histologic Type
Hemostatic Disorders
Vascular Diseases
Cardiovascular Diseases
Blood Protein Disorders
Hematologic Diseases
Hemorrhagic Disorders
Lymphoproliferative Disorders
Immunoproliferative Disorders
Immune System Diseases
Immunologic Factors
Physiological Effects of Drugs
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Growth Substances
Growth Inhibitors
Antineoplastic Agents
Histone Deacetylase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action